Bioventus Stock Today
BVS Stock | USD 4.15 0.16 3.71% |
Performance0 of 100
| Odds Of DistressOver 64
|
Bioventus is selling for under 4.15 as of the 25th of April 2024; that is -3.71 percent decrease since the beginning of the trading day. The stock's lowest day price was 4.15. Bioventus has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Bioventus are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 11th of February 2021 | Category Healthcare | Classification Health Care |
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the bodys natural healing process in the United States and internationally. The company was founded in 2011 and is headquartered in Durham, North Carolina. The company has 63.38 M outstanding shares of which 787.34 K shares are currently shorted by investors with about 4.43 days to cover. More on Bioventus
Moving together with Bioventus Stock
0.65 | EVH | Evolent Health Financial Report 1st of May 2024 | PairCorr |
0.73 | RCM | R1 RCM Inc Earnings Call This Week | PairCorr |
Moving against Bioventus Stock
0.42 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 21st of May 2024
Bioventus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Bioventus' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Bioventus or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO President | Robert Claypoole | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thematic Idea | Medical Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Old Name | Vistry Group PLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, HNX 30, NASDAQ Composite, SPASX All Technology, NASDAQ Health Care, Australia All Ordinaries, Medical Equipment, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation Analysts covering Bioventus report their recommendations after researching Bioventus' financial statements, talking to executives and customers, or listening in on Bioventus' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Bioventus. The Bioventus consensus assessment is calculated by taking the average forecast from all of the analysts covering Bioventus. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength Based on the key indicators related to Bioventus' liquidity, profitability, solvency, and operating efficiency, Bioventus may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. Financial strength of Bioventus is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bioventus' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bioventus' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bioventus' financial leverage. It provides some insight into what part of Bioventus' total assets is financed by creditors.
|
Bioventus (BVS) is traded on NASDAQ Exchange in USA. It is located in 4721 Emperor Boulevard, Durham, NC, United States, 27703 and employs 970 people. Bioventus is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 273.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bioventus's market, we take the total number of its shares issued and multiply it by Bioventus's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bioventus runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 63.38 M outstanding shares of which 787.34 K shares are currently shorted by investors with about 4.43 days to cover.
Bioventus has about 34.36 M in cash with 15.34 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Bioventus Probability Of Bankruptcy
Ownership AllocationBioventus holds a total of 63.38 Million outstanding shares. Over half of Bioventus' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Bioventus. Please watch out for any change in the institutional holdings of Bioventus as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bioventus Ownership Details
Bioventus Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Bioventus jumping above the current price in 90 days from now is roughly 97.0%. The Bioventus probability density function shows the probability of Bioventus stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.2164 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bioventus will likely underperform. Additionally, bioventus has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Bioventus to move above the current price in 90 days from now is roughly 97.0 (This Bioventus probability density function shows the probability of Bioventus Stock to fall within a particular range of prices over 90 days) .
Bioventus Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Bioventus that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bioventus' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bioventus' value.Instituion | Recorded On | Shares | |
Morgan Stanley - Brokerage Accounts | 2023-12-31 | 193.5 K | |
Marshall Wace Asset Management Ltd | 2023-12-31 | 190.6 K | |
Charles Schwab Investment Management Inc | 2023-12-31 | 180.5 K | |
Qube Research & Technologies | 2023-12-31 | 178.5 K | |
Jane Street Group, Llc | 2023-12-31 | 155.7 K | |
Stephens Inc | 2023-12-31 | 142.7 K | |
Renaissance Technologies Corp | 2023-12-31 | 135.2 K | |
Mariner Wealth Advisors, Llc | 2023-12-31 | 130.6 K | |
Two Sigma Advisers, Llc | 2023-12-31 | 127.9 K | |
Essex Woodlands Health Ventures | 2023-12-31 | 13 M | |
Nantahala Capital Management, Llc | 2023-12-31 | 12 M |
Bioventus Historical Income Statement
Bioventus Income Statement is one of the three primary financial statements used for reporting Bioventus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bioventus revenue and expense. Bioventus Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Bioventus' Interest Expense is comparatively stable compared to the past year. Operating Income is likely to gain to about 16.8 M in 2024, whereas Total Revenue is likely to drop slightly above 386.8 M in 2024. View More FundamentalsBioventus Stock Against Markets
Picking the right benchmark for Bioventus stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Bioventus stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Bioventus is critical whether you are bullish or bearish towards Bioventus at a given time. Please also check how Bioventus' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bioventus without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
All Next | Launch Module |
Bioventus Corporate Management
Elected by the shareholders, the Bioventus' board of directors comprises two types of representatives: Bioventus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bioventus. The board's role is to monitor Bioventus' management team and ensure that shareholders' interests are well served. Bioventus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bioventus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kenneth Reali | CEO Director | Profile | |
MBA BS | Senior Operations | Profile | |
Helen Leupold | Senior Officer | Profile | |
Katrina Church | VP Officer | Profile | |
Alessandraa Pavesio | VP Officer | Profile | |
Larry Chen | Managing Pacific | Profile |
How to buy Bioventus Stock?
Before investing in Bioventus, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Bioventus. To buy Bioventus stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Bioventus. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Bioventus stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Bioventus stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Bioventus stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Bioventus, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.
Already Invested in Bioventus?
The danger of trading Bioventus is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Bioventus is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Bioventus. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Bioventus is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Bioventus is a strong investment it is important to analyze Bioventus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bioventus' future performance. For an informed investment choice regarding Bioventus Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Bioventus Stock analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Bioventus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioventus. If investors know Bioventus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioventus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 8.178 | Quarterly Revenue Growth 0.076 | Return On Assets 0.0012 | Return On Equity (0.38) |
The market value of Bioventus is measured differently than its book value, which is the value of Bioventus that is recorded on the company's balance sheet. Investors also form their own opinion of Bioventus' value that differs from its market value or its book value, called intrinsic value, which is Bioventus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioventus' market value can be influenced by many factors that don't directly affect Bioventus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioventus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioventus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioventus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.